uhCG/EGF

Phase 1Small molecule

HHenry Ford Health System

uhCG/EGF is one of 42 small molecule programs targeting Graft Versus Host Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Graft Versus Host DiseaseRecruiting

Graft Versus Host DiseasePhase 1

Recruiting

Competition

Competitive Landscape

48 competitors in Graft Versus Host Disease

#DrugCompanyPhaseTrials

Trexall

Jazz Pharmaceuticals

Approved

15 2

Neoral

Novartis

Approved

9 3

Medrol

Pfizer

Approved

4 4

Selzentry

GSK

Approved

1 5

Nipent

Defitelio

Olumiant

Gleevec

Qvar

3 10

Cellcept

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Recruiting

Graft Versus Host Disease

NCT04886726

Clinical

Trials by Indication[1]

Graft Versus Host Disease1 trial

PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis

Recruiting·HHenry Ford Health System·Phase 1·NCT04886726·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for uhCG/EGF. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — uhCG/EGF compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for uhCG/EGF. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henry Ford Health System company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: HHenry Ford Health System

uhCG/EGF

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Graft Versus Host Disease1 trial

References

Drug Info

Quick Facts

Related News